CATX
PERSPECTIVE THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $13 | $3.76 | -72% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $13 | $3.76 | -72% |
| Two Sigma Investments | Q1 2025(8Q snapshot) | 5Q | $3.02 | $3.76 | +25% |
| AQR Capital Management | Q2 2026(8Q snapshot) | 1Q | $3.85 | $3.76 | -2% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 3× in & out | Q3 2025 | Q2 2026 | → $3.85 | -1% |
| Renaissance Technologies 3× in & out | Q1 2026 | Q2 2026 | → $3.86 | -23% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Perspective Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Mar 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001761768-26-000003Mar 4, 2026
- Form 40001748615-26-000002Mar 4, 2026
- Form 40001397331-26-000002Mar 4, 2026
- Form 40001283301-26-000008Mar 4, 2026
- Form 40001393007-26-000002Mar 4, 2026
- Form 40001535289-26-000003Mar 4, 2026
- Form 40001375410-26-000003Mar 4, 2026
- Form 40001965071-26-000002Mar 4, 2026
- Form 40001193125-25-283953Nov 17, 2025
- Form 40001193125-25-281626Nov 14, 2025
- Form 40000950170-25-113245Sep 5, 2025
- Form 40000950170-25-113243Sep 5, 2025
- Form 40000950170-25-048775Apr 1, 2025
- Form 40000950170-25-048698Apr 1, 2025
- Form 40000950170-25-048696Apr 1, 2025
Fundamentals
XBRL · PERSPECTIVE THERAPEUTICS, INC.Annual figures sourced directly from PERSPECTIVE THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Perspective Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 1, 2026
- 8-KMaterial eventMay 27, 2026
- 8-KMaterial eventMay 22, 2026
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventApr 20, 2026
- DEF 14AProxy statementApr 16, 2026
- 8-KMaterial eventApr 1, 2026
- 10-KAnnual reportMar 16, 2026
- 8-KMaterial eventMar 16, 2026
- 8-KMaterial eventFeb 3, 2026
- 8-KMaterial eventFeb 2, 2026
- 8-KMaterial eventJan 14, 2026
- 8-KMaterial eventJan 12, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q2 2026 | open | $3.85 | $3.76 | -2% |
| Renaissance Technologies | Q1 2026 | Q2 2026 | $5.02 | $3.86 | -23% |
| Point72 Asset Management | Q3 2025 | Q2 2026 | $3.90 | $3.85 | -1% |
| Renaissance Technologies | Q2 2025 | Q3 2025 | $2.16 | $3.81 | +76% |
| Two Sigma Investments | Q1 2025 | open | $3.02 | $3.76 | +25% |
| Millennium Management | Q1 2025 | open | $3.02 | $3.76 | +25% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $3.02 | $2.41 | -20% |
| Citadel Advisors | Q3 2024 | open | $13 | $3.76 | -72% |
| Millennium Management | Q3 2024 | Q4 2024 | $13 | $8.92 | -33% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $13 | $8.92 | -33% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $12 | $9.93 | -17% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.